-
admin
Posts
State, Municipal Leaders Celebrate the Official Launch of Rhode Island’s Largest Closed Landfill Solar Site
Developed by NuGen Capital Management, the Bristol Landfill Solar Project will generate enough renewable energy to power 700+ homes and businesses BRISTOL, R.I., July 25,...
Phillips Edison & Company Acquires Grocery-Anchored Shopping Center in Partnership with Cohen & Steers Income Opportunities REIT, Inc.
CINCINNATI, July 25, 2024 (GLOBE NEWSWIRE) — Phillips Edison & Company, Inc. (Nasdaq: PECO) (“PECO”), one of the nation’s largest owners and operators of grocery-anchored...
The Honest Company to Report Second Quarter Financial Results on August 8, 2024
LOS ANGELES, July 25, 2024 (GLOBE NEWSWIRE) — The Honest Company (NASDAQ: HNST), a personal care company dedicated to creating clean- and sustainably-designed products, today...
Hermès International: 2024 Half-year Results
Half-year information report as at the end of June 2024 Robust sales and results in the first halfRevenue amounted to €7.5 billion(Revenue increased by...
BUREAU VERITAS – Early impact of the new LEAP | 28 strategy boosting revenue and improving margins in the first half; 2024 revenue outlook upgraded
PRESS RELEASE Neuilly-sur-Seine, France – July 25, 2024 Early impact of the new LEAP | 28 strategy boosting revenue and improving margins1 in the first...
OnKure Announces the Appointment of Dylan Hartley as Chief Scientific Officer
BOULDER, Colo., July 25, 2024 (GLOBE NEWSWIRE) — OnKure, Inc. today announced that Dylan Hartley, Ph.D. has been appointed to the position of Chief Scientific...
BioAtla Highlighted Clinical Program and Pipeline Updates at Virtual R&D Day
Clinical benefit observed among non-small cell lung cancer (NSCLC) patients harboring mutant KRAS (mKRAS) variants in the Phase 2 mecbotamab vedotin (CAB-AXL-ADC) study; AXL tumoral...
23andMe to Report Q1 FY2025 Financial Results
SOUTH SAN FRANCISCO, Calif., July 25, 2024 (GLOBE NEWSWIRE) — 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a...
Travere Therapeutics to Report Second Quarter 2024 Financial Results
SAN DIEGO, July 25, 2024 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced it will report second quarter 2024 financial results on Thursday,...
FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis’ UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) Treatment
ALL represents 10% of all leukemia cases in the United States, progresses rapidly, and is typically fatal within weeks or months if left untreated1 There...
